Table 5 Summary of the differences in OS, PFS, toxicities, number of BCLC A or B patients, and number of patients without vascular invasion or extrahepatic metastasis

Number of BCLC A or B patients (proportion)

0 (0%)

60 (18%)

68 (18%)

104 (21.8%)

Number of patients with no vascular invasion (proportion)

13 (19%)

91 (62%)

247 (77%)

755 (79.1%)

Child Pugh A

34 (45%)

336 (100%)

371 (100%)

478 (100%)

Overall Survival in months (95% CI)

13.7

(8.41–21.8)

19.2

(17.0 – 23.7)

16.4

(13.9–18.4)

13.6

(12.1–14.9)

Progression free survival in months (95% CI)

7.46

(3.55–16.26)

6.9

(5.7–8.6)

3.7

(3.1–3.9)

7.4

(6.9–8.8)

≥3 Toxicities

12 (16%)

143 (43%)

81 (22%)

270 (56.7%)